These compounds are often catalytic and result in degradation of the target protein rather than inhibition. The rapidly growing TPD field has largely focused on the development of degraders for intracellular proteins by induction of proteolysis (PROTACs). We and others have developed bifunctional molecules that target extracellular proteins for endocytosis and subsequent lysosomal degradation, which we termed molecular degraders of extracellular proteins (MoDEs), and have also been called LyTACs. Technologies have been developed that induce endocytosis by targeting the asialoglycoprotein receptor ,the cation-independent mannose-6-phosphate receptor , integrin , CXCR7 cytokine receptor , scavenger receptors , transferrin receptor , and low-density lipoprotein receptor-related protein 1. While PROTACs have been developed to degrade intracellular tau in neuronal tauopathy models , extracellular TPD technology has not yet been studied in brain cells.